Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
COLUMN
Emerging Immunotherapy of Cancer: 2
Keiji Nakamura, Ph.D. Pharma Forum Institute Lambrolizumab (MK-3475) of Merck & Co. MK-3475 is also a humanized IgG4 mab against PD-1, especially effective for melanoma, as designated as a breakthrough therapy by the FDA in 2013 and its second cancer…
To read the full story
COLUMN
- New York Note - 2: The Tariff Roller Coaster
November 5, 2026
- Japan’s Healthcare Pulse: An 18-Month Market Snapshot
October 30, 2026
- New York Note - 1: JETRO’s Role in Connecting Japan with the World
October 23, 2026
- Outside the Bubble: Lunch with Pharma Delegates
September 30, 2026
- The One Mistake on Your Resume
August 31, 2026
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…